Allogene Therapeutics Inc (ALLO)

Dec 31, 2025

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail

Dec 31, 2025

Dec 21, 2025

Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда

Dec 21, 2025

Dec 20, 2025

Why Allogene Therapeutics Inc. stock is favored by pension fundsTreasury Yields & Daily Entry Point Trade Alerts - Улправда

Dec 20, 2025

Dec 19, 2025

Why Allogene Therapeutics Inc. stock is seen as undervaluedMarket Activity Recap & Verified Stock Trade Ideas - Улправда

Dec 19, 2025

Dec 19, 2025

Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Levels & Weekly Stock Breakout Alerts - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Is Allogene Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Macro Moves & AI Driven Price Predictions - Улправда

Dec 18, 2025

Dec 17, 2025

Allogene Therapeutics Earnings Notes - Trefis

Dec 17, 2025

Dec 16, 2025

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga

Dec 16, 2025

Dec 16, 2025

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights By Investing.com - Investing.com South Africa

Dec 16, 2025

Dec 15, 2025

Allogene Therapeutics (ALLO) Solidifies Global Rights to Cema-ce - GuruFocus

Dec 15, 2025

Dec 15, 2025

Arbitration ruling reaffirms Allogene’s control of cancer therapy By Investing.com - Investing.com Canada

Dec 15, 2025

Dec 15, 2025

Arbitration ruling reaffirms Allogene’s control of cancer therapy - Investing.com India

Dec 15, 2025

Dec 15, 2025

Allogene Therapeutics Reaffirms Control of Cemacabtagene Ansegedleucel Following Arbitration Ruling - Quiver Quantitative

Dec 15, 2025

Dec 15, 2025

Allogene stock rises after favorable arbitration ruling reaffirms therapy rights - Investing.com

Dec 15, 2025

Dec 15, 2025

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - sahmcapital.com

Dec 15, 2025

Dec 15, 2025

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewswire

Dec 15, 2025

Dec 15, 2025

Allogene (NASDAQ: ALLO) arbitration clears path to global cema-cel rights deal - Stock Titan

Dec 15, 2025

Dec 14, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 14, 2025

Dec 12, 2025

December 2025 Penny Stocks Worth Watching - simplywall.st

Dec 12, 2025

Dec 09, 2025

Allogene Therapeutics advances ALPHA3 trial to battle relapse fears - Traders Union

Dec 09, 2025

Dec 04, 2025

Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser

Dec 04, 2025

Dec 04, 2025

Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union

Dec 04, 2025

Dec 01, 2025

Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union

Dec 01, 2025

Nov 29, 2025

Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛

Nov 29, 2025

Nov 29, 2025

Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat

Nov 29, 2025

Nov 26, 2025

Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media

Nov 26, 2025

Nov 25, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Nov 25, 2025

Nov 24, 2025

Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union

Nov 24, 2025

Nov 24, 2025

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN

Nov 24, 2025

Nov 23, 2025

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

Nov 23, 2025

Nov 20, 2025

Can SBC Exports Limited Deliver Through Market Peaks and TroughsResistance Zone Identification & Build Winning Portfolio - earlytimes.in

Nov 20, 2025

Nov 20, 2025

Allogene Therapeutics reports Q3 EPS (19c), consensus (23c) - MSN

Nov 20, 2025

Nov 20, 2025

Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union

Nov 20, 2025

Nov 20, 2025

CAR-T in NHL Treatment Market Size is estimated to grow by 2034, - openPR.com

Nov 20, 2025

Nov 19, 2025

Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com

Nov 19, 2025

Nov 19, 2025

Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com

Nov 19, 2025

Nov 19, 2025

[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

Nov 19, 2025

Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Allogene Therapeutics advances ALLO-329 cell therapy to transform autoimmune care - Traders Union

Nov 19, 2025

Nov 19, 2025

ALLO (Allogene Therapeutics) Construction In Progress : $0.00 Mil (As of Sep. 2025) - GuruFocus

Nov 19, 2025

Nov 19, 2025

Patient Square Capital LP Grows Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat

Nov 19, 2025

Nov 19, 2025

Will breakout in Allogene Therapeutics Inc. lead to full recovery2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com

Nov 19, 2025

Nov 18, 2025

What candlestick patterns are forming on Allogene Therapeutics Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com

Nov 18, 2025

Nov 18, 2025

Allogene Therapeutics at Jefferies Conference: Strategic Advances in CAR-T Therapy - Investing.com Canada

Nov 18, 2025

Nov 17, 2025

VP Beneski Files To Sell 786 Of Allogene Therapeutics Inc [ALLO] - TradingView

Nov 17, 2025